Skip to main content
. 2022 Jun 17;13:916701. doi: 10.3389/fimmu.2022.916701

Figure 1.

Figure 1

Expression of CXCL16 on monocytes is associated with enhanced clinical disease activity and cardiovascular risk. (A) Flow cytometry analysis of CXCL16 expression on monocyte subpopulations defined by gating for CD14 and CD16 expression in PBMC: classical monocytes (CD14++ CD16-, R1 green), intermediate monocytes (CD14++ CD16+, R2 blue) and non-classical monocytes (CD14low CD16++, R3, red), mean and SD of healthy controls (n= 14; unfilled dots) and patients with psoriasis vulgaris (n= 39; filled dots), Welch’s t test. (B) Correlation of CXCL16 expression on all monocytes of psoriatic patients (n=39) and clinical disease activity (PASI), Pearson’s correlation. (C) Correlation for each monocyte subset defined by color indicated in (A) and PASI score, Pearson’s correlation. (D) Mean and SD of PASI (unpaired t test) and PROCAM (Mann-Whitney test) of normal-weight (unfilled triangles; n=19) and obese psoriatic patients (filled triangles; n=20). (E) Correlation of chemokine expression with cardiovascular risk (PROCAM score); and body-mass-index (BMI). Each dot represents an individual patient, Pearson correlation. (F) CXCL16 expression on monocytes in psoriatic patients without atherosclerosis (n= 6; unfilled trapezoid) or with atherosclerosis (n= 9; filled trapezoid), mean and SD, unpaired t test. *p < 0.05; **p < 0.01; ***< 0.001. ns, not significant.